



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	77.66
Trade Time:	4:00 PM ET May 23, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	74.13 - 147.17
Volume	864

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 24, 2018
[Celgene Corporation Announces Additional \\$3 Billion Share Repurchase Authorization and Plans to Execute a \\$2 Billion Accelerated Share Repurchase Program](#)

May 22, 2018
[Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018](#)

May 16, 2018
[Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology \(ASCO\) Scientific Sessions](#)

May 14, 2018
[Celgene Corporation to Webcast at Upcoming Investor Conferences and Events](#)

May 4, 2018
[Celgene Reports First Quarter 2018 Operating and Financial Results](#)

Upcoming Events [\[View all \]](#)

May 24, 2018 1:30 PM ET
[R&D Deep Dive on Multiple Myeloma](#)

May 30, 2018 3:00 PM ET
[Bernstein Thirty-Fourth Annual Strategic Decisions Conference 2018](#)

Financials [\[View all \]](#)

Feb 7, 2018
[Annual Report \(10-K\)](#)

Apr 30, 2018
[Proxy Statement \(DEF 14A\)](#)

May 4, 2018
[Quarterly Report \(10-Q\)](#)

Oct 26, 2017
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017
[Quarterly Report \(10-Q\)](#)